.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,699,498

« Back to Dashboard
Patent 6,699,498 protects NEUPRO and is included in one NDA. There has been one Paragraph IV challenge on Neupro.

This patent has twenty-nine patent family members in twenty-two countries.

Summary for Patent: 6,699,498

Title: Transdermal therapeutic systems having improved stability and their production
Abstract:This invention provides for, inter alia, a transdermal therapeutic system comprising at least one therapeutically active substance, which is oxidizable by hydroperoxides, wherein the amount of oxidative degradation of said active substances(s) and the corresponding formation of oxidative degradation products is reduced, which comprises one or more constituents of said transdermal therapeutic system being in contact with said active substance(s), wherein the sum of the peroxide number(s) (PON) of each of said constituents related to their percentage of the whole amount of said constituents as expressed by the formula ##EQU1## where N is the percentage content of the whole amount of said constituents in the TTS, n is the number of said constituents in the TTS, i is the running number PON is the peroxide number of each of the constituents, is not greater than 20.
Inventor(s): Muller; Walter (Neuwied, DE)
Assignee: LTS Lohmann Therapie-Systeme AG (Andernach, DE)
Application Number:09/723,130
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound;
Patent Metrics:
Source: PatentQuant.com
Field: Medical technology
Back Citations: 10th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ucb Inc
NEUPRO
rotigotine
FILM, EXTENDED RELEASE;TRANSDERMAL021829-004Apr 2, 2012RXNo6,699,498► subscribeY
Ucb Inc
NEUPRO
rotigotine
FILM, EXTENDED RELEASE;TRANSDERMAL021829-001May 9, 2007RXYes6,699,498► subscribeY
Ucb Inc
NEUPRO
rotigotine
FILM, EXTENDED RELEASE;TRANSDERMAL021829-005Apr 2, 2012RXNo6,699,498► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,699,498

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany199 57 401Nov 29, 1999
Germany100 54 713Nov 04, 2000

International Patent Family for Patent: 6,699,498

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2266735► subscribe
Russian Federation2002118325► subscribe
Portugal1233763► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc